AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier in a dosage form adapted for intranasal, ~~transmucosal,~~ transdermal, or intradermal administration sufficient to establish in a patient a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about a maximum of 10.0 picograms desmopressin per mL plasma/serum and to decrease urine production~~, with the proviso that said dosage form does not produce a desmopressin plasma/serum concentration exceeding about 10 pg/ml~~.

2. (Canceled)

3. (Previously Presented) The pharmaceutical composition of claim 1 comprising from about 0.05 μg to about 10 μg desmopressin.

4. (Previously presented) The pharmaceutical composition of claim 1 comprising from about 0.1 μg to about 2 μg desmopressin.

5. (Canceled)

6. (Currently Amended) The pharmaceutical composition of claim 1 in a dosage form adapted for transdermal delivery and comprising a patch, gel, cream, ointment, or iontophore ~~of an orodispersible solid adapted for sublingual or buccal administration~~.

7. (Currently Amended) The pharmaceutical composition of claim 1 adapted for intradermal administration ~~further~~ comprising a patch ~~an open matrix network, said open matrix network comprising a water-soluble or water-dispersible carrier material that is inert towards desmopressin~~.

8. (Canceled)

9. (Previously Presented) The pharmaceutical composition of claim 1 in a dosage form sufficient to establishes in a patient a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picograms desmopressin per mL plasma/serum.

10-26 (Canceled).

27. (Currently Amended) A pharmaceutical dosage form comprising desmopressin and a pharmaceutically acceptable carrier adapted for intranasal~~, transmucosal, transdermal, or intradermal~~ administration which when administered to a patient establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about a maximum of 10.0 picograms desmopressin per mL plasma/serum for a time between four and six hours and decreases urine production.

28. (Previously Presented) The composition of claim 27 which establishes a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picograms desmopressin per mL plasma/serum.

29. (New) A pharmaceutical dosage form comprising desmopressin and a pharmaceutically acceptable carrier for intradermal or transdermal administration which when administered to a patient establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about a maximum of 10.0 picograms desmopressin per mL plasma/serum for a time between four and six hours and decreases urine production.

30. (New) The dosage form of claim 29 which establishes a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picograms desmopressin per mL plasma/serum.

31. (New) The dosage form of claim 29 comprising between 0.05 μg and 10 μg desmopressin.

32. (New) The dosage form of claim 29 adapted for intradermal administration comprising a patch.

33. (New) The dosage form of claim 29 adapted for transdermal delivery and comprising a patch, gel, cream, ointment, or iontophore.